New CNS-Focused Biotech Cerevance Launches With Takeda Backing

 
• By Lucie Ellis-Taitt
  
Human anatomy
Cerevance will focus on its portfolio of early-stage CNS compounds, including some Takeda assets • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business